Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Sell
15
WST Quote, Financials, Valuation and Earnings
Last price:
$190.80
Seasonality move
:
7.24%
Day range:
$188.35 - $206.21
52-week range:
$188.35 - $394.42
Dividend yield:
0.43%
P/E ratio:
28.46x
P/S ratio:
4.85x
P/B ratio:
5.13x
Volume:
897.5K
Avg. volume:
978.9K
1-year change:
-51.5%
Market cap:
$13.8B
Revenue:
$2.9B
EPS (TTM):
$6.69
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$686.3M | $1.23 | 1.26% | -4.78% | $285.01 |
|
BAX
Baxter International
|
$2.6B | $0.48 | -25.67% | 590.29% | $39.74 |
|
BDX
Becton Dickinson &
|
$5.4B | $3.28 | 6.1% | 77.32% | $275.03 |
|
PDEX
Pro-Dex
|
$17.7M | $0.47 | 23.84% | 147.37% | $54.00 |
|
RMD
ResMed
|
$1.3B | $2.36 | 7.21% | 15.65% | $269.42 |
|
TFX
Teleflex
|
$699.4M | $2.88 | 1.37% | 104.93% | $165.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$190.39 | $285.01 | $13.8B | 28.46x | $0.21 | 0.43% | 4.85x |
|
BAX
Baxter International
|
$27.97 | $39.74 | $14.3B | 167.20x | $0.17 | 3.29% | 1.11x |
|
BDX
Becton Dickinson &
|
$200.83 | $275.03 | $57.7B | 33.36x | $1.04 | 1.98% | 2.83x |
|
PDEX
Pro-Dex
|
$54.66 | $54.00 | $178.2M | 27.33x | $0.00 | 0% | 3.05x |
|
RMD
ResMed
|
$204.54 | $269.42 | $30B | 24.15x | $0.53 | 1.01% | 6.12x |
|
TFX
Teleflex
|
$127.14 | $165.22 | $5.9B | 89.54x | $0.34 | 1.07% | 1.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 0.908 | 0.92% | 1.88x |
|
BAX
Baxter International
|
65.34% | 0.105 | 88.33% | 0.54x |
|
BDX
Becton Dickinson &
|
42.67% | 0.146 | 28.8% | 0.44x |
|
PDEX
Pro-Dex
|
33.99% | 0.894 | 10.75% | 1.35x |
|
RMD
ResMed
|
11.35% | 0.237 | 2% | 1.74x |
|
TFX
Teleflex
|
27.91% | 0.883 | 20.11% | 1.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$273.6M | $169.8M | 16.88% | 18.15% | 21.92% | $85.2M |
|
BAX
Baxter International
|
$959M | -$1M | -3.07% | -8.24% | -15.29% | $351M |
|
BDX
Becton Dickinson &
|
$2.2B | $546M | 3.92% | 6.75% | 8.92% | $588M |
|
PDEX
Pro-Dex
|
$5.1M | $2.7M | 15.21% | 21.59% | 16.61% | -$4.7M |
|
RMD
ResMed
|
$751.3M | $417.2M | 21.74% | 25.56% | 32.54% | $285.2M |
|
TFX
Teleflex
|
$439.9M | $140.8M | 1.13% | 1.57% | -13.59% | $170.4M |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or BAX?
Baxter International has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -18.6%. West Pharmaceutical Services's return on equity of 18.15% beat Baxter International's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B BAXBaxter International34.84% -$1.00 $20.2B -
What do Analysts Say About WST or BAX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 49.7%. On the other hand Baxter International has an analysts' consensus of $39.74 which suggests that it could grow by 42.08%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 BAXBaxter International4 11 1 -
Is WST or BAX More Risky?
West Pharmaceutical Services has a beta of 1.221, which suggesting that the stock is 22.112% more volatile than S&P 500. In comparison Baxter International has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.462%.
-
Which is a Better Dividend Stock WST or BAX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.43%. Baxter International offers a yield of 3.29% to investors and pays a quarterly dividend of $0.17 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BAX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Baxter International quarterly revenues of $2.8B. West Pharmaceutical Services's net income of $130.1M is higher than Baxter International's net income of -$512M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 28.46x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 4.85x versus 1.11x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services4.85x 28.46x $748.8M $130.1M BAXBaxter International1.11x 167.20x $2.8B -$512M
-
Which has Higher Returns WST or BDX?
Becton Dickinson & has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 5.86%. West Pharmaceutical Services's return on equity of 18.15% beat Becton Dickinson &'s return on equity of 6.75%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B BDXBecton Dickinson &43.25% $1.04 $44B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 49.7%. On the other hand Becton Dickinson & has an analysts' consensus of $275.03 which suggests that it could grow by 36.95%. Given that West Pharmaceutical Services has higher upside potential than Becton Dickinson &, analysts believe West Pharmaceutical Services is more attractive than Becton Dickinson &.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 BDXBecton Dickinson &8 4 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services has a beta of 1.221, which suggesting that the stock is 22.112% more volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.131%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.43%. Becton Dickinson & offers a yield of 1.98% to investors and pays a quarterly dividend of $1.04 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. West Pharmaceutical Services's net income of $130.1M is lower than Becton Dickinson &'s net income of $303M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 28.46x while Becton Dickinson &'s PE ratio is 33.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 4.85x versus 2.83x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services4.85x 28.46x $748.8M $130.1M BDXBecton Dickinson &2.83x 33.36x $5.2B $303M
-
Which has Higher Returns WST or PDEX?
Pro-Dex has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 12.15%. West Pharmaceutical Services's return on equity of 18.15% beat Pro-Dex's return on equity of 21.59%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B PDEXPro-Dex30.2% $0.61 $48.2M -
What do Analysts Say About WST or PDEX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 49.7%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could fall by -1.21%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 PDEXPro-Dex1 0 0 -
Is WST or PDEX More Risky?
West Pharmaceutical Services has a beta of 1.221, which suggesting that the stock is 22.112% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.026%.
-
Which is a Better Dividend Stock WST or PDEX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.43%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PDEX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are larger than Pro-Dex quarterly revenues of $16.8M. West Pharmaceutical Services's net income of $130.1M is higher than Pro-Dex's net income of $2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 28.46x while Pro-Dex's PE ratio is 27.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 4.85x versus 3.05x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services4.85x 28.46x $748.8M $130.1M PDEXPro-Dex3.05x 27.33x $16.8M $2M
-
Which has Higher Returns WST or RMD?
ResMed has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 26.88%. West Pharmaceutical Services's return on equity of 18.15% beat ResMed's return on equity of 25.56%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B RMDResMed58.6% $2.34 $5.9B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 49.7%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 31.72%. Given that West Pharmaceutical Services has higher upside potential than ResMed, analysts believe West Pharmaceutical Services is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 RMDResMed8 6 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services has a beta of 1.221, which suggesting that the stock is 22.112% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.43%. ResMed offers a yield of 1.01% to investors and pays a quarterly dividend of $0.53 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than ResMed quarterly revenues of $1.3B. West Pharmaceutical Services's net income of $130.1M is lower than ResMed's net income of $344.6M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 28.46x while ResMed's PE ratio is 24.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 4.85x versus 6.12x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services4.85x 28.46x $748.8M $130.1M RMDResMed6.12x 24.15x $1.3B $344.6M
-
Which has Higher Returns WST or TFX?
Teleflex has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -17.18%. West Pharmaceutical Services's return on equity of 18.15% beat Teleflex's return on equity of 1.57%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B TFXTeleflex55.31% -$2.95 $5.9B -
What do Analysts Say About WST or TFX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 49.7%. On the other hand Teleflex has an analysts' consensus of $165.22 which suggests that it could grow by 29.95%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 TFXTeleflex0 11 0 -
Is WST or TFX More Risky?
West Pharmaceutical Services has a beta of 1.221, which suggesting that the stock is 22.112% more volatile than S&P 500. In comparison Teleflex has a beta of 1.191, suggesting its more volatile than the S&P 500 by 19.095%.
-
Which is a Better Dividend Stock WST or TFX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.43%. Teleflex offers a yield of 1.07% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TFX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Teleflex quarterly revenues of $795.4M. West Pharmaceutical Services's net income of $130.1M is higher than Teleflex's net income of -$136.7M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 28.46x while Teleflex's PE ratio is 89.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 4.85x versus 1.96x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services4.85x 28.46x $748.8M $130.1M TFXTeleflex1.96x 89.54x $795.4M -$136.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How Bad Will the Stock Market Get?
In recent trading days, global stock markets have seen massive…
Is JOBY Stock a Buy, Sell or Hold?
Joby Aviation (NYSE:JOBY) got started with the big idea of…
Stock Ideas
Sell
36
Is MSFT Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 30x
Sell
30
Is AAPL Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 28x
Sell
33
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 33x
Alerts
Buy
55
SLNO alert for Apr 9
Soleno Therapeutics [SLNO] is up 0.47% over the past day.
Sell
20
HELE alert for Apr 9
Helen Of Troy [HELE] is down 0.22% over the past day.
Sell
18
OXM alert for Apr 9
Oxford Industries [OXM] is up 2.02% over the past day.
